Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) – HC Wainwright issued their Q2 2024 EPS estimates for Ikena Oncology in a research report issued on Thursday, November 9th. HC Wainwright analyst A. Maldonado anticipates that the company will earn ($0.44) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Ikena Oncology’s current full-year earnings is ($1.55) per share.
Ikena Oncology (NASDAQ:IKNA – Get Free Report) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.04. Ikena Oncology had a negative net margin of 327.46% and a negative return on equity of 42.93%. The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $3.63 million.
Ikena Oncology Stock Up 9.8 %
IKNA opened at $1.46 on Monday. Ikena Oncology has a 52-week low of $1.02 and a 52-week high of $7.64. The firm’s 50-day moving average price is $4.02 and its 200-day moving average price is $5.25. The company has a market cap of $61.76 million, a P/E ratio of -0.90 and a beta of 0.78.
Hedge Funds Weigh In On Ikena Oncology
Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in shares of Ikena Oncology during the 4th quarter worth approximately $27,000. California State Teachers Retirement System acquired a new stake in shares of Ikena Oncology during the 2nd quarter worth approximately $46,000. SG Americas Securities LLC acquired a new stake in shares of Ikena Oncology during the 3rd quarter worth approximately $46,000. Wells Fargo & Company MN grew its stake in shares of Ikena Oncology by 2,913.6% during the 2nd quarter. Wells Fargo & Company MN now owns 8,227 shares of the company’s stock worth $54,000 after purchasing an additional 7,954 shares during the period. Finally, American International Group Inc. acquired a new stake in shares of Ikena Oncology during the 2nd quarter worth approximately $67,000. Institutional investors and hedge funds own 86.01% of the company’s stock.
Ikena Oncology Company Profile
Ikena Oncology, Inc operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway.
- Five stocks we like better than Ikena Oncology
- How to Invest in Artificial Intelligence
- MarketBeat Week in Review – 11/6 – 11/10
- Bank Stocks – Best Bank Stocks to Invest In
- Data giants MongoDB and Snowflake just got upgraded
- What Makes a Stock a Good Dividend Stock?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.